RhumbLine Advisers’s Forte Biosciences FBRX Stock Holding History

RhumbLine Advisers’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Buy	+22,149	New	+$525K	﹤0.01%	2812
2021 Q3	–	Sell	-360	Closed	-$303K	–	3035
2021 Q2	$303K	Buy	+360	New	+$324K	﹤0.01%	2783
2020 Q2	–	Sell	-71	Closed	-$32K	–	3076
2020 Q1	$32K	Hold	71	–	–	﹤0.01%	2886
2019 Q4	$14K	Sell	71 -1	-1%	-$227	﹤0.01%	2942
2019 Q3	$18K	Hold	72	–	–	﹤0.01%	2947
2019 Q2	$181K	Buy	72 +4	+6%	+$11.9K	﹤0.01%	2813
2019 Q1	$277K	Buy	68 +6	+10%	+$23.2K	﹤0.01%	2584
2018 Q4	$191K	Buy	62 +21	+51%	+$90.4K	﹤0.01%	2749
2018 Q3	$241K	Sell	41 -3	-7%	-$11.4K	﹤0.01%	2631
2018 Q2	$154K	Buy	44 +4	+10%	+$14.6K	﹤0.01%	2797
2018 Q1	$178K	Buy	+40	New	+$185K	﹤0.01%	2635

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

RhumbLine Advisers's FBRX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Forte Biosciences (FBRX) in Q2 2026: 22,149 shares worth $471K. The stake represents ﹤0.01% of the portfolio and ranks #2812 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in FBRX as recently as Q2 2021.

RhumbLine Advisers first reported a position in FBRX in Q1 2018 and has held it in 11 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

RhumbLine Advisers held 22,149 shares of Forte Biosciences worth $471K as of Q2 2026.
Forte Biosciences was a new RhumbLine Advisers position in Q2 2026.
Forte Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2812 holding.
RhumbLine Advisers first reported a position in Forte Biosciences in Q1 2018 and has held it in 11 quarters since.
86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.